ArticleCommunications medicine2025
Antimicrobial resistance of Enterobacterales in Central Africa: a systematic review and meta-analysis.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- High Burden of Multidrug-Resistant Bacteria in Eastern Democratic Republic of the Congo: A Retrospective Hospital-Based Study.Infection and drug resistance · 2026Article
- Economic Barriers to Antimicrobial Susceptibility Testing as a Structural Contributor to Antimicrobial Resistance in Low- and Middle-Income Countries: A Narrative Review.Infection and drug resistance · 2026Review
- Article
- Antimicrobial resistance of Enterobacterales in Central Africa: a systematic review and meta-analysis.Communications medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial resistance (AMR) in Enterobacterales is a growing concern in sub-Saharan Africa, yet data remain scarce for Central Africa.
methodsWe conducted a systematic review and meta-analysis (2008-2024) to estimate the prevalence of extended spectrum ß-lactamase-producing Enterobacterales (ESBL-EB) and AMR frequency across nine Central African countries. Systematic searching strategy and risk of bias assessment followed PRISMA guidelines. Prevalence or frequencies and 95% confidence intervals were estimated using a random effects meta-model with the Der Simonian and Laird method.
resultsHere we show an ESBL-EB pooled prevalence of 22% (41% for carriage and 10% in clinical samples) for the 24 selected articles assessing ESBL-EB. For the 26 selected articles assessing AMR frequency, we find it is high for cotrimoxazole (63-81%), amoxicillin/clavulanic acid (43-63%), ciprofloxacin (24-33%), and remains lower for nitrofurantoin (12-18%) and amikacin (13-19%). We provide pooled estimates for alternative agents and highlight the near-total absence of data for WHO Reserve antibiotics, including carbapenems, newer β-lactam/β-lactamase inhibitors, and fosfomycin. Significant heterogeneity and high exclusion rate due to risk of bias reflect major diagnostic limitations in the region.
conclusionsThe high prevalence of AMR in Central Africa underscores the urgent need to strengthen antimicrobial susceptibility testing capacities, restrict empirical use of key antibiotics, and ensure equitable access to effective antimicrobials. Without coordinated investments for microbiology capacities scale-up, prescription regulation, strategies for water, sanitation and hygiene, and infection prevention and control, patient outcomes and regional AMR containment will be jeopardized.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.